References
- Jaffe E, Harris N, Stein H, ., editors. Pathology and genetics. Tumours of haematopoietic and lymphoid tissues. 3rd ed. Lyon: IARC; 2001. pp 58–59.
- Schmitt-Graeff A, Thiele J, Zuk I, . Essential thrombocythemia with ringed sideroblasts: a heterogeneous spectrum of diseases, but not a distinct entity. Haematologica 2002;87:392–399.
- Swerdlow S, Campo E, Harris N, ., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008.
- Hellstrom-Lindberg E. Significance of JAK2 and TET2 mutations in myelodysplastic syndromes. Blood Rev 2010;24:83–90.
- Atallah E, Nussenzveig R, Yin CC, . Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis. Leukemia 2008;22:1295–1298.
- Raya JM, Arenillas L, Domingo A, . Refractory anemia with ringed sideroblasts associated with thrombocytosis: comparative analysis of marked with non-marked thrombocytosis, and relationship with JAK2 V617F mutational status. Int J Hematol 2008;88:387–395.
- Ceesay MM, Lea NC, Ingram W, . The JAK2 V617F mutation is rare in RARS but common in RARS-T. Leukemia 2006;20:2060–2061.
- Szpurka H, Jankowska AM, Makishima H, . Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations. Leuk Res 2010;34:969–973.
- Gondek LP, Tiu R, O’Keefe CL, . Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 2008;111:1534–1542.
- Huls G, Mulder AB, Rosati S, . Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis. Blood 2010;116:180–182.